Academy, which is an open forum and the main entities representing the Brazilian academy take part, was created to debate, elaborate and propose solutions to be further submitted for approval at CGen. The Chamber has been very active and have already proposed many resolutions and technical orientations which have been approved by CGen that have improved the process. The Chamber is also involved with discussions and proposals for the new version of SisGen that is being proposed to ameliorate and correct the problems identified during the use of the current system since the end of 2017. The expectation is that the process will be improved and will allow the compliance of the legislation in a more optimised and efficient way.
In the European Union (EU), user compliance with the NP is regulated by Regulation No. 511/2014 of the European Parliament and establishes due diligence measures for users of GR in the EU, which basically means a user must prove they followed the laws in place when conducting research and sampling abroad. This regulation applies to GR collected in a country that is a Party to the NP after the entry into force of the NP for the EU (12 October 2014) or after the country implements national legislation 1 . The European law is not retroactive and does not apply to 'old' GR although the legal definition of access is important. In practice it makes a difference whether GR is newly isolated from an environment or acquired from an ex-situ collection and different countries handle this in different ways (see the discussion on the definition of Access to GR below). The law does not require collections to comply with non-Nagoya CBD obligations (i.e. GR that is out of NP) although the DSMZ is diligent about ensuring access and benefit sharing (ABS) obligations are fulfilled and requests documentation from depositors accordingly.
The role of culture collections as major suppliers of GR was recognised in the EU regulation with the establishment of a 'Register of Collections' in which a collection voluntarily fulfils part of the due diligence obligations of the user by seeking NP-related 'permits' before distributing GR. In order to do this systematically, a collection must demonstrate that their management practices enable them to comply with national NP regimes for all incoming material. Only collections that fall within EU jurisdiction can apply for a 'registered' status, although their products continue to be available for users around the world and the NP/CBD information they provide is undoubtedly still helpful in fulfilling non-EU due diligence obligations.
In March 2018, the Leibniz Institute German Collection of Microorganisms and Cell Cultures GmbH (DSMZ) became the first collection in the EU register. The DSMZ submitted a 14-page application (along with 11 supporting documents) to the German Agency for Nature Conservation (BfN) in November 2017, and was officially approved by BfN on 18 March 2018. The application took around four months to prepare by a two-person science-legal team (AHS and HMP) and was a high priority for the DSMZ Scientific Director, Professor Jörg Overmann. There were significant personnel investments from quality management, scientific, and administrative staff with costs estimated around e200 000. The application was also supported in a close partnership with the BfN. Below we share our experiences of obtaining the registered collection status, and challenges and opportunities that arose during this process.
Compliance with the Nagoya Protocol
Many microbial collections collect up-front scientific and administrative information through accession forms, but the CBD and NP extend the information required and can complicate the deposit process. Here are the steps we took towards NP compliance in our collection:
(1) Geographical scope
The first step was to review our collection catalog and confirm that all strains collected in 2014 and beyond (NP entry into force) had a country of origin associated with them. For strains that pre-dated the CBD we accepted, if necessary, 'country of origin unknown' accompanied by evidence from our records or the literature that the collection date was pre-1992.
We then edited and standardised records with 'imprecise' countries of origin: states which no longer exist (e.g. Czechoslovakia), large geographic areas (e.g. Europe), islands (e.g. Hawaii), and dependent territories (e.g. Puerto Rico), duplicates (e.g. Burma and Myanmar), and spelling errors. We applied the ISO 3166 code for the representation of names of countries and their subdivisions and corrected our records accordingly to only include recognised sovereign states. With this list in hand, for all future deposits, we instituted the use of a drop down menu in our online accession form and mandatory geographical coordinates to avoid uncertainty. We added to the ISO list, areas not regulated by the
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Nagoya Protocol: Antarctica and the high seas (international waters), both regulated by separate UN treaties.
(2) Temporal scope Whether a new strain is in or out of CBD/NP scope is dependent on geography and time. As such, sampling date is essential to determine whether access to GR is regulated. We reviewed all strains in the collection that had no sampling date information and an accession date after 1992. We used information from the deposit form, literature, and internal records to determine whether a sampling date could be determined. When no collection date was available, we substituted the accession date (when a strain was deposited) which is a more conservative value and added 'sampled before + accession date'.
(3) Legal scope (PIC and MAT)
The CBD and NP invented a new vocabulary for granting access to GR -'prior informed consent' (PIC) and 'mutually agreed terms' (MAT). These can be none, one, or two or more documents depending on how the national legislation works and they can carry different names such as 'research permit' or 'material transfer agreement' although their content must reflect PIC/MAT and be issued by the appropriate CBD/NP authority (see ABS-CH discussion below). At the beginning of our compliance check, very few strains in our collection had PIC/MAT documents, meaning they were 'in scope'. But, recognising that the 'in scope' strains and, thus, their associated documents would grow over time, we established both a new standard operating procedure and IT system to enable transparent review of PIC/MAT. This decision tree for determining legal compliance is outlined in Figure 1 national focal points. We prepared an infographic to explain the minimal requirements on information applied to a deposited strain 3 . 
The complex NP legal 'potpourri'
All Parties to the CBD are required under international law to provide information on their national legislation and contact information. However, in practice, the ABS-CH is not legally binding The NP provides a legal framework for access and benefit sharing among Parties and the EU Register of Collections is restricted to NP Parties. However, it is important to remember that a non-NP-Party may have national laws that govern access to their resources. Brazil is probably the most well-known example of a NP non-party country which has developed its own national legislation regulating access to GR 5 . Despite its non-Party status, the DSMZ is doing its best to follow Brazilian national laws.
Outlook
In a time of increasing legal overheads, it is important that microbial But even with good exchange and networking, the process of strain deposition is simply becoming more complex. Several authors have pointed out the negative impact of the NP regulations on biodiversity assessments and conservation efforts 6, 7 . The situation in microbiological research is not much different. Long and complicated applications for sampling permits discourage many scientists (e.g. [8] [9] [10] ) and additional problems can be expected when a strain needs to be sent out of the country of origin and deposited in an open collection. The number of strains deposited in the DSMZ for the purpose of taxonomic description has rapidly dropped down from nearly half of deposits (48% and 46% in 2014 and 2015, respectively) to 16% in 2018. We also have observed a trend towards growing numbers of strains originating from countries who declared free access to their GR or from the U.S., a country that is not a Party to the CBD. Another interesting trend is the growing interest on the deposition of 'old' material, strains isolated before the NP and CBD, as a part of safeguarding collections from retiring scientists.
Obtaining the Registered collection status is a long-term investment which is aimed to provide additional service and value for our customers, who would otherwise be responsible for obtaining and checking the NP documents themselves and to demonstrate good will and competence to provider countries. To date, the registered collection status has not led to an increase in sales, but we have heard from colleagues that they appreciate the additional quality control and legal clarity. Over the past year, there has been growing interest from our customers in the strain-related information regarding the NP, perhaps due to the year-old EU due diligence declaration 4 . Overall, we feel strongly that the Registered Collection was the right decision on balance and look forward to working with European and international colleagues in assisting microbiologists with the legal overhead that is now our daily reality.
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The Bazeley Oration, first given in 1992, is sponsored by Commonwealth Serum Laboratories (CSL) to honour the achievements of a former director, Percival (Val) Landon Bazeley, who was one of Australia's most distinguished microbiologists. One of these achievements was spearheading the production of penicillin by CSL.
Bazeley was born in Orbost in Victoria in 1909. He studied veterinary science at Melbourne University and after graduation joined CSL as an assistant veterinary research officer in 1938. At the outbreak of WW2 he enlisted but continued to work at CSL until his posting to Papua New Guinea in 1941. However, shortly before he left, the Oxford group published their seminal paper on the therapeutic use of penicillin. Another great Australian, Bill Keogh, recognised the significance of this work and convinced the War Cabinet that Australia needed to be self-sufficient and that Bazeley was the man to make this happen. Bazeley was ordered home and promptly dispatched to the USA where he spent the next three months visiting US manufacturers. On his return Bazeley set himself the target of producing penicillin within six weeks. By February 1944, 10 weeks after his return, a sizeable quantity of material had been produced and by April, CSL was able to provide penicillin to civilians, the first country in the world to do so. A truly amazing feat for an extraordinary man who became a national hero and in 1956 Director of CSL.
Taken from notes provided by Professor Ian Gust.
